Gene therapies offer real hope for patients with serious conditions like spinal muscular atrophy and sickle cell disease. These treatments can work with just one dose, but that dose can cost more than three million dollars. So how can we make sure patients who need them can actually get them?

In this episode of The BioDisruptors Podcast, we explore the challenges of paying for gene therapy. We explain why these treatments are so expensive, how insurance plans are trying to manage the cost, and what new ideas might help, such as paying based on results or spreading payments over time.

If you want to understand how science, money, and policy all come together in modern medicine, this episode is for you.

Featured Article: Managing the Challenges ofPaying for Gene Therapy:Strategies for Market Action and Policy Reform (https://icer.org/wp-content/uploads/2024/04/Managing-the-Challenges-of-Paying-for-Gene-Therapy-_-ICER-NEWDIGS-White-Paper-2024_final.pdf)